These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 9028553)
1. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. Takenaka K; Gondo H; Tanimoto K; Nagafuji K; Fujisaki T; Mizuno S; Miyamoto T; Okamura T; Hayashi S; Eto T; Osaki K; Yamasaki K; Shibuya T; Harada N; Teshima T; Matsuishi E; Minematsu T; Minamishima Y; Harada M; Niho Y Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553 [TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278 [TBL] [Abstract][Full Text] [Related]
3. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors. Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851 [TBL] [Abstract][Full Text] [Related]
4. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bacigalupo A; Tedone E; Isaza A; Soracco M; Van Lint MT; Sanna A; Frassoni F; Occhini D; Gualandi F; Lamparelli T Bone Marrow Transplant; 1995 Jul; 16(1):155-61. PubMed ID: 7581116 [TBL] [Abstract][Full Text] [Related]
5. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313 [TBL] [Abstract][Full Text] [Related]
6. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302 [TBL] [Abstract][Full Text] [Related]
7. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis. Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929 [TBL] [Abstract][Full Text] [Related]
8. Surveillance of cytomegalovirus infections in bone marrow transplant in Trieste: seven years' experience. D'Agaro P; Andolina M; Burgnich P; Samar E; Campello C Haematologica; 2000 Nov; 85(11 Suppl):54-7. PubMed ID: 11268325 [TBL] [Abstract][Full Text] [Related]
9. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322 [TBL] [Abstract][Full Text] [Related]
10. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150 [TBL] [Abstract][Full Text] [Related]
11. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection. Kim DH; Kim JG; Lee NY; Sung WJ; Sohn SK; Suh JS; Lee KS; Lee KB Bone Marrow Transplant; 2004 Jul; 34(1):21-7. PubMed ID: 15133483 [TBL] [Abstract][Full Text] [Related]
13. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation. Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752 [TBL] [Abstract][Full Text] [Related]
14. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976 [TBL] [Abstract][Full Text] [Related]
15. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus. Mikulska M; Raiola AM; Bruzzi P; Varaldo R; Annunziata S; Lamparelli T; Frassoni F; Tedone E; Galano B; Bacigalupo A; Viscoli C Biol Blood Marrow Transplant; 2012 Jan; 18(1):92-9. PubMed ID: 21689774 [TBL] [Abstract][Full Text] [Related]
16. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [TBL] [Abstract][Full Text] [Related]
17. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bacigalupo A; Tedone E; Van Lint MT; Trespi G; Lonngren M; Sanna MA; Moro F; Frassoni F; Occhini D; Gualandi F Bone Marrow Transplant; 1994 Jun; 13(6):783-8. PubMed ID: 7920315 [TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289 [TBL] [Abstract][Full Text] [Related]
19. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up. Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297 [TBL] [Abstract][Full Text] [Related]
20. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Bacigalupo A; Tedone E; Sanna MA; Moro F; Van Lint MT; Grazi G; Balestreri M; Frassoni F; Occhini D; Gualandi F Haematologica; 1992; 77(6):507-13. PubMed ID: 1337746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]